FDA Wins Injunction Against Endotec “Custom” Ankles And Knees
This article was originally published in The Gray Sheet
Executive Summary
Orthopedic device maker Endotec's Buechel-Pappas ankles are not custom devices and therefore not exempt from pre-market requirements, according to a recent U.S. appeals court decision
You may also be interested in...
Endotec Case Sheds Light, But Not Enough, On Custom Devices, Says Attorney
A Florida judge's recent ruling in U.S. v. Endotec highlights the need for FDA guidance on regulation of custom devices, according to a leading expert on custom device law
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.
US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios
Forthcoming guidance is expected to describe areas of “low-hanging fruit” and those that are more challenging for use of the expedited pathway, Center for Biologics Evaluation and Research Director Peter Marks said.